Catalyst Dossier · compiled by CeliA 🧫

Mind Medicine (MindMed) Inc. (MNMD)

Medicinal Chemicals & Botanical Products · market cap $515M

Research and calibrated estimates, not financial advice — verify before acting.

Next catalyst

2026-07-15 (est.)

Phase 3

Pipeline

programs

Upcoming events

next 90d+

Dossier

Not yet

generate it

The catalyst path

2026-07-15 (est.)Phase 3 · MM120 (LSD D-Tartrate)imp 9/10

Pipeline

Asset	Phase	Indication
MM-120	Phase 2	ADHD
MM402 (R-enantiomer of 3,4-methylenedioxymethamphetamine (MDMA))	Phase 2	Autism Spectrum Disorder
MM120 (LSD D-Tartrate)	Phase 3	Generalized Anxiety Disorder

Price & technical context

3-month

+21.4%

6-month

+84.3%

12-month

+114.6%

52-wk range

$4.89–$14.87

vs 50-day MA

+18.5%

vs 200-day MA

+54.8%

Realized vol

72.2%

Max drawdown

-58.4%

Daily closes through 2026-01-13. Realized vol annualized; max drawdown over ~2 years.

The full dossier is a Pro feature

Thesis, bull & bear, the if-approved scenario, financials, smart-money signals and risks — compiled by CeliA. The catalyst path & pipeline above are free.

See Pro

Sources & data

SEC filings — EDGAR filings for MNMD (10-K, 10-Q, S-3, 13D/G, Form 4)
Clinical trials — 3 registered trials on ClinicalTrials.gov (per-trial NCT links in the pipeline)
Market & financial data — Financial Modeling Prep / financialdata.net — prices, statements, key metrics, insider & institutional filings.
Regulatory — openFDA, FDA advisory & PDUFA calendars.

Approval odds use historical phase base rates; the if-approved scenario is illustrative (see its note). Figures trace to the sources above — verify before acting.

Data from CatalystAlert (ClinicalTrials.gov, SEC EDGAR, openFDA, Financial Modeling Prep). Compiled by CeliA. Not financial advice.